Orchard Therapeutics (ORTX) Stock Forecast, Price & News

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Orchard Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares.
View analyst ratings for Orchard Therapeutics or view top-rated stocks.

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 777,900 shares, a drop of 48.8% from the April 15th total of 1,520,000 shares. Based on an average trading volume of 582,300 shares, the short-interest ratio is presently 1.3 days. Currently, 0.7% of the company's shares are sold short.
View Orchard Therapeutics' Short Interest.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Orchard Therapeutics.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) posted its quarterly earnings data on Wednesday, March, 30th. The company reported ($0.29) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.29). The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.65 million. During the same quarter last year, the company posted ($0.34) EPS.
View Orchard Therapeutics' earnings history.

What price target have analysts set for ORTX?

6 Wall Street analysts have issued 12-month price targets for Orchard Therapeutics' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate Orchard Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,700.0% from the stock's current price.
View analysts' price targets for Orchard Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:

• Dr. Bobby Gaspar Ph.D., M.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 57, Pay $712.41k)
• Mr. Frank E. Thomas, Pres & COO (Age 52, Pay $586.18k)
• Dr. Nicoletta Loggia Ph.D., Chief Technical Officer
• Dr. Fulvio Mavilio Ph.D., Chief Scientific Officer
• Ms. Renee T. Leck, Director of Investor Relations
• Benjamin Navon, Director of Corp. Communications
• Mr. John Cerio, Chief Human Resource Officer
• Dr. Anne Dupraz-Poiseau, Chief Devel. Officer
• Mr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial Operations
• Mr. Braden Parker, Chief Commercial Officer

Who are some of Orchard Therapeutics' key competitors?

Some companies that are related to Orchard Therapeutics include Adaptimmune Therapeutics (ADAP), Autolus Therapeutics (AUTL), Jounce Therapeutics (JNCE), Innate Pharma (IPHA), Voyager Therapeutics (VYGR), Dynamics Special Purpose (DYNS), Molecular Partners (MOLN), bluebird bio (BLUE), Checkmate Pharmaceuticals (CMPI), Innate Pharma (IPHYF), Sutro Biopharma (STRO), Lineage Cell Therapeutics (LCTX), Scholar Rock (SRRK), Genfit (GNFT) and DBV Technologies (DBVT).
View all of ORTX's competitors.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.35%), SG Americas Securities LLC (0.84%), Renaissance Technologies LLC (0.65%), BlackRock Inc. (0.60%), GSA Capital Partners LLP (0.30%) and New York State Common Retirement Fund (0.26%). Company insiders that own Orchard Therapeutics stock include Bobby Gaspar, Fmr Llc and Frank E Thomas.
View institutional ownership trends for Orchard Therapeutics.

Which institutional investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Renaissance Technologies LLC, JPMorgan Chase & Co., Sei Investments Co., Group One Trading L.P., Harbor Capital Advisors Inc., Goldman Sachs Group Inc., and Simplex Trading LLC.
View insider buying and selling activity for Orchard Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Orchard Therapeutics stock?

ORTX stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Forefront Analytics LLC, and GSA Capital Partners LLP. Company insiders that have bought Orchard Therapeutics stock in the last two years include Bobby Gaspar, and Frank E Thomas.
View insider buying and selling activity for Orchard Therapeutics or or view top insider-buying stocks.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $0.50.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $62.95 million and generates $1.67 million in revenue each year. The company earns $-144.58 million in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 259 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 442038088286.